Razoxane
Razoxane (pronounced: rah-ZOX-ane) is a chemotherapeutic agent used in the treatment of cancer. It is also known by its trade name, ICRF-187.
Etymology
The term "Razoxane" is derived from its chemical structure, which contains a razoxane ring. The prefix "ra-" is derived from the Latin "ratis", meaning "raft", which refers to the flat, planar structure of the razoxane ring. The suffix "-oxane" is a common suffix in organic chemistry, used to denote a cyclic ether.
Pharmacology
Razoxane is a bisdioxopiperazine derivative that acts as a topoisomerase II inhibitor. It interferes with the DNA repair mechanism in cancer cells, leading to cell death. It is also known to have radioprotective properties, protecting normal tissues from the harmful effects of radiation therapy.
Clinical Use
Razoxane is used in the treatment of various types of cancer, including breast cancer, soft tissue sarcoma, and small cell lung cancer. It is often used in combination with other chemotherapeutic agents to enhance their effectiveness.
Side Effects
Like all chemotherapeutic agents, Razoxane can have side effects. These may include nausea, vomiting, hair loss, and bone marrow suppression. It can also cause cardiotoxicity, a potentially serious side effect that can lead to heart failure.
Related Terms
External links
- Medical encyclopedia article on Razoxane
- Wikipedia's article - Razoxane
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski